LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

Meanwhile, Merck shares climbed 2 per cent to $54.07, after the drugmaker was also handed an “overweight” rating and had its price target lifted to $66 from $64.

Jefferies analysts initiated Eli Lilly & Co. (NYSE: LLY) with a Hold rating and $290 price target and Merck & Company Inc (NYSE: MRK) with a Buy rating and $125 price target in separate notes to ...

Eli Lilly and Merck disclosed that they have each received requests tied to drug pricing from the US attorney general’s office in Pennsylvania.

Results for the second quarter were a bit better than expected. Non-GAAP earnings were $2.13 per share, better than the $2.02 ...

However, I'm not advocating going out and buying either Lilly or Merck right now. In my view, there are too many better stocks for investors to buy that provide stronger growth prospects.

According to TipRanks.com, Wright is a 5-star analyst with an average return of 12.3% and a 61.9% success rate. Wright covers the Healthcare sector, focusing on stocks such as Phibro Animal Health, ...

Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101. The ...

Merck experienced a rather disappointing year in 2013, with its shares underperforming the S&P 500, as did sector peer Eli Lilly, although AbbVie delivered more impressive share price growth -- over ...

By Sam Boughedda Jefferies analysts initiated Eli Lilly & Co. (NYSE: LLY) with a Hold rating and $290 price target and Merck & Company Inc (NYSE: MRK) with a Buy rating and $125 price target in ...